AbbVie

Immunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation.